LAB.00046 Testing for Biochemical Markers for Alzheimer’s Disease

This policy addresses laboratory testing for biochemical markers of Alzheimer’s disease, specifically cerebrospinal fluid (CSF) assays of amyloid‑beta, including Aβ42, Aβ42:Aβ40 ratio, or Aβ42:phospho‑tau. Coverage is medically necessary only when performed on CSF and used to guide consideration of amyloid‑beta–targeting therapy. All other uses—such as diagnostic testing with biochemical markers (including tau protein, long‑form amyloid‑beta, neural thread protein) when these criteria are not met, or any screening in asymptomatic individuals—are investigational and not medically necessary.

"Measurement of long-form amyloid beta is consideredmedically necessarywhen criteria A, B and C are met:"

Sign up to see full coverage criteria, indications, and limitations.